Format

Send to

Choose Destination
Exp Mol Pathol. 2018 Dec;105(3):328-333. doi: 10.1016/j.yexmp.2018.10.007. Epub 2018 Oct 11.

Analysis of point mutations and copy number variation in Grade II and III meningioma.

Author information

1
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
2
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
3
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
4
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
5
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: sdahiya@wustl.edu.

Abstract

Meningiomas are among the most common tumors of the adult central nervous system (CNS). They are classified by the World Health Organization into three pathologic grades with increasing severity: grade I are benign with favorable treatment outcomes and low recurrence rates while grade III display malignant behavior and poor progression-free survival. Previous studies have shown that inactivation of NF-2 is the most common genetic event in high-grade meningioma; however, there is dearth of molecular data to distinguish grade II (AM-II) from the even more aggressive grade III (AM-III). As part of a routine diagnostic workup, 19 AM-II and 5 AM-III were submitted for targeted sequencing on a panel of twenty-four genes relevant to CNS tumors. The data generated during the course of clinical care was collected and re-analyzed with the aim of identifying molecular features to distinguish AM-II and AM-III. Our cases contained several well-characterized, potentially actionable mutations, but we did not find any novel, recurrent sequence variants. Copy number variations were common in both AM-II and AM-III; chr22q loss was the most prevalent followed in decreasing frequency by losses of chr1p, chr14q, and chr10. In particular, chr10 loss was noted in 4 of 5 AM-III cases but none of the AM-II cases. This suggests that chr10 loss may serve as a diagnostic and perhaps a prognostic marker to differentiate AM-II from AM-III. If confirmed in larger studies, our finding could further aid the classification of meningioma.

KEYWORDS:

Clinical sequencing.; Copy number variation.; Meningioma; Next-generation sequencing.

PMID:
30316860
DOI:
10.1016/j.yexmp.2018.10.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center